Researchers performed a post hoc analysis of endoscopic outcomes in participants of the pivotal SONIC trial that compared the efficacy of azathioprine, infliximab, and the
IBD
IBD
Ileal and Rectal Ulcers Heal Slower and May Be More Refractory to Therapy Than Colonic Lesions in Crohn’s Disease
Low Incidence of Colorectal Cancer After Endoscopic Dysplasia Resection in Patients With IBD
Given the paucity of high-quality outcome data, the optimal management of polypoid and/or nonpolypoid colonic lesions in IBD is an ongoing debate. Guidelines recommend that
Recycled Precolectomy Anti-Tumor Necrosis Factor Does Not Work for Chronic Pouchitis
Following total proctocolectomy with restorative ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC), about one-third of patients develop chronic pouchitis. Treatment of antibiotic-refractory and Crohn’s
Relapse Half as Likely With Ulcerative Colitis in Clinical and Endoscopic Remission Than Clinical Remission with Mild Endoscopic Disease Activity
The current treatment target in ulcerative colitis (UC) is clinical and endoscopic remission, defined by patient-reported outcomes and a Mayo endoscopic subscore of 0 or
Postoperative Endoscopic Recurrence of Ileal Lesions, Not Anastomotic Lesions, More Likely to Predict Long-Term Outcomes in Crohn’s Disease
Early endoscopic recurrence of Crohn’s disease (CD) following ileocolonic resection predicts clinical recurrence, the need for therapy escalation, and repeat surgery. The significance of mild
Fecal Microbiota Transplantation Shows Promise for IBS in the Most Recent Randomized Controlled Trial
Alterations of the gut microbiota in irritable bowel syndrome (IBS) have been described. Observational studies on fecal microbiota transplantation (FMT) aiming to restore eubiosis have
High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn’s Disease
The optimal vitamin D level for patients with IBD is highly debated. While a level >20 ng/L is sufficient for bone health even in high-risk
A Significant Bidirectional Association Between IBD and Celiac Disease: IBD Is More Common in Celiac Disease and Vice Versa
No Benefit From Antibiotics for Uncomplicated Diverticulitis
A randomized, placebo-controlled, double-blinded trial showed no benefit from antibiotic therapy for the management of uncomplicated acute diverticulitis. Hospitalized patients (N=180) in New Zealand and
Daily 81 mg of Aspirin OK in Patients With IBD
Monika Fischer, MD, reviewing Patel P, et al. Inflamm Bowel Dis 2020 Mar 27. Nonsteroidal anti-inflammatory medications are known to increase the risk of IBD
Achieving Deep Remission Early, No Matter How, Is Best Way to Decrease Crohn’s Disease Progression
Monika Fischer, MD, reviewing Ungaro RC, et al. Gastroenterology 2020 Mar 26. The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program recommended deep remission
Serum Biomarkers Predict Crohn’s Disease Diagnosis 5 Years in Advance, but Not Ulcerative Colitis
Monika Fischer, MD, reviewing Torres J, et al. Gastroenterology 2020 Mar 9. Early intervention appears to be the key to mitigating severe complications of Crohn’s
Shortening Ustekinumab Interval to Every 4 Weeks Associated With Increased Rates of Clinical and Biological Remission in Patients With Crohn’s Disease
Monika Fischer, MD, reviewing Ollech JE, et al. Clin Gastroenterol Hepatol 2020 Feb 25. This single-center retrospective study evaluated the outcomes of 110 patients with
Healthy Lifestyle Recommended for General Public Associated With Significant Survival in Adult-Onset IBD
Monika Fischer, MD, reviewing Lo CH, et al. Clin Gastroenterol Hepatol 2020 Mar 3. Several studies in the non-IBD population have shown that a healthy
First Selective Oral Jak1 Inhibitor Induces Remission in Ulcerative Colitis
Monika Fischer, MD, reviewing Sandborn WJ, et al. Gastroenterology 2020 Feb 21. Upadacitinib, a selective Janus kinase 1 (Jak1) inhibitor (60-fold selective for Jak1 over
Anti-Tumor Necrosis Factor Should Be Considered for Ulcerative Proctitis Refractory to Conventional Therapy
Monika Fischer, MD, reviewing Pineton de Chambrun G, et al. Clin Gastroenterol Hepatol 2020 Mar. Treatment of ulcerative proctitis that is unresponsive to mesalamine and
Predictors of Colectomy at 1 Year in Severe Ulcerative Colitis
Monika Fischer, MD, reviewing Le Baut G, et al. Clin Gastroenterol Hepatol 2020 Jan 9. A French IBD consortium studied 270 hospitalized patients with severe
Mediterranean Diet May Reduce the Risk of Crohn’s Disease Onset in Middle-Aged or Older Adults
Monika Fischer, MD, reviewing Khalili H, et al. Gut 2019 Jan 3. A large prospective cohort study from Sweden (N=83,147; age range, 45-79 years; mean
Higher Infliximab Trough Concentrations Needed for Mucosal Healing in Crohn’s Disease Than Previously Suggested
Monika Fischer, MD, reviewing Dreesen E, et al. Clin Gastroenterol Hepatol 2020 Jan 16. The previously published TAILORIX study failed to show benefits from proactive therapeutic drug
Microscopic Colitis Increases the Risk of Late-Onset IBD
Monika Fischer, MD, reviewing Khalili H, et al. Gastroenterology 2020 Jan 8. In a nationwide Swedish cohort study, the diagnosis of microscopic colitis (N=14,000) was
Inpatient Fecal Microbiota Transplantation Program Decreases C difficile-Related Mortality and Colectomy
Monika Fischer, MD, reviewing Cheng YW, et al. Clin Gastroenterol Hepatol 2020 Jan 7. Severe and fulminant forms of C difficile infection (CDI) are often refractory to
Crohn’s Disease Patients with HLA-DQA1*05 Allele at Increased Risk of Antidrug Antibody Development
Monika Fischer, MD, reviewing Sazonovs A, et al. Gastroenterology 2020 Jan. In this genome-wide association study, 1240 patients with biologic-naive Crohn’s disease were treated with
Proactive Versus Reactive Monitoring of Anti-TNF Drug Levels: A Randomized Controlled Trial
Kenneth R. McQuaid, MD, FASGE reviewing Assa A, et al. Gastroenterology 2019 Oct. In IBD, loss of response to anti-TNF therapy is more likely with
Vedolizumab Is More Efficacious Than Adalimumab for UC in a Head-to-Head Trial
Monika Fischer, MD, FASGE reviewing Sands BE, et al. N Engl J Med 2019 Sep 26. A head-to-head phase 3 trial involving patients with moderately
Ustekinumab Is Efficacious for Induction and Maintenance of UC
Monika Fischer, MD, FASGE reviewing Sands BE, et al. N Engl J Med 2019 Sep 26. Ustekinumab, an antagonist of the p40 subunit of interleukin-12
Subcutaneous Vedolizumab Is as Effective as Intravenous Formulation for Maintenance of Remission in Patients With Ulcerative Colitis
Vedolizumab is a highly effective and safe treatment option for patients with moderately severe and severe ulcerative colitis, with over 40% of patients achieving clinical
Therapeutic Drug Monitoring of Vedolizumab: Should Trough Levels Be Measured…and When?
In IBD patients treated with anti-TNF agents, therapeutic drug monitoring (TDM) is commonly used to optimize therapy, reduce risk of antibody formation, and determine mechanisms
